Parexel has been, and still is, at the forefront of many of the recent advances in GI cancer. Colon Cancer and Pancreatic Cancer remain major causes of cancer morbidity, and we are actively engaged inmany trials evaluating novel and promising agents in these disease areas. Significant advances have been seen with earlier use of immunotherapy, both as front-line therapy for advanced gastric cancer and as postoperative therapy of resected esophageal cancer. A novel antibody-drug-conjugate targeting HER2 provides new hope for patients with this subset of gastric cancers. The same therapy is under evaluation in colon cancer and we are very proud to be part of this endeavor.
275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.